Review

Rev Diabet Stud, 2005, 2(2):61-69 DOI 10.1900/RDS.2005.2.61

New Therapeutic Strategies for the Treatment of Type 2 Diabetes Mellitus Based on Incretins

Baptist Gallwitz

Department of Medicine IV, Eberhard-Karls-University, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany, e-mail: baptist.gallwitz@med.uni-tuebingen.de

Keywords: type 2 diabetes, incretin, incretin mimetics, GLP-1, DPP-IV inhibitors, vildagliptin, sitagliptin

Abstract

Orally ingested glucose leads to a greater insulin response compared to intravenously administered glucose leading to identical postprandial plasma glucose excursions, a phenomenon referred to as the "incretin effect". The incretin effect comprises up to 60% of the postprandial insulin secretion and is diminished in type 2 diabetes. One of the very important gastrointestinal hormones promoting this effect is glucagon-like peptide 1 (GLP-1). It only stimulates insulin secretion and normalizes blood glucose in humans under hyperglycemic conditions, therefore it does not cause hypoglycemia. Other important physiological actions of GLP-1 are the inhibition of glucagon secretion and gastric emptying. It further acts as a neurotransmitter in the hypothalamus stimulating satiety. In vitro and animal data demonstrated that GLP-1 increases β-cell mass by stimulating islet cell neogenesis and by inhibiting apoptosis of islets. In humans, the improvement of β-cell function can be indirectly observed from the increased insulin secretory capacity after GLP-1 infusions. GLP-1 represents an attractive therapeutic principle for type 2 diabetes. However, native GLP-1 is degraded rapidly upon exogenous administration and is therefore not feasible for routine therapy. The first long-acting GLP-1 analog ("incretin mimetic") Exenatide (Byetta®) has just been approved for type 2 diabetes therapy. Other compounds are being investigated in clinical trials (e.g. liraglutide®, CJC1131®). Dipeptidyl-peptidase IV inhibitors (DPP-IV inhibitors; e.g. Vildagliptin®, Sitagliptin®) that inhibit the enzyme responsible for incretin degradation are also under study.

Fulltext: HTML , PDF (363KB)


This article has been cited by other articles:

The role of nanotechnology in diabetes treatment: current and future perspectives

Samuel D, Bharali D, Mousa SA

Int J Nanotechnol 2011. 8(1-2):53-65

A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice

Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC

J Control Release 2009. 133(3):172-177

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 008 Group

Int J Clin Pract 2009. 63(1):46-55

Managing the beta-cell with GLP-1 in type 2 diabetes

Gallwitz B

Brit J Diabetes Vasc Dis 2008. 8(Suppl 2):S19-S25

Anti-diabetic Agents in Type 2 Diabetes: A Review of New Data Presented and Discussed on the EASD meeting in Rome, 2008

de Valk HW

Rev Diabet Stud 2008. 5(3):184-188

Incretin-based antidiabetics: GLP-1 mimetics and DPP-IV inhibitors

Gallwitz B

Diabetologie und Stoffwechsel 2008. 3(4):234-240

Exenatide - a turning point in pharmacotherapy of NIDDM

Malhotra P, Gupta OP, Parihar A, Bala S, Gupta G

J Med Educ Res 2008. 10(4):201-202

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

Pratley RE, Gilbert M

Rev Diabet Stud 2008. 5(2):73-94

Serum stability of peptides

Jenssen H, Aspmo SI

Methods Mol Biol 2008. 494:177-86

Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens

Brunton S

Diabetes Technol Ther 2008. 10(4):247-256

How insulin receptor substrate proteins regulate the metabolic capacity of the liver - implications for health and disease

Fritsche L, Weigert C, Häring HU, Lehmann R

Curr Med Chem 2008. 15(13):1316-1329

Glucagon-like Peptide-1 and Type 2 Diabetes Mellitus

Lan Z, Li CP

Medical Recapitulate 2008. 14(5):714-716

Exenatide: a new step in type 2 diabetes treatment

Waddingham S

Brit J Prim Care Nurs 2008. 5(1):26-30

Molecules at the microscope: Exenatide, the incretin-mimetic prototype

Salari P

Giornale del Medico 2007. 33(20):13

DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety

De Valk HW

Rev Diabet Stud 2007. 4(3):126-133

New pharmacotherapeutic approaches for diabetes mellitus

Goldberg T, Pham DQ

Pharm Times 2007. July, p 68-75

The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes

Triggle CR

Drugs Today 2007. 43(11):815-826

FDA new drug approvals in 2006

Wynn RL

Gen Dent 2007. 55(4):275-279